Akari Therapeutics Delays Quarterly SEC Filing

Akari Therapeutics ( (AKTX) ) has released a notification of late filing.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Akari Therapeutics, Plc has filed a Form 12b-25 to notify investors that it will delay its Quarterly Report on Form 10-Q (Quarter Report) for the period ended March 31, 2026. The company says the filing relates specifically to its Form 10-Q (Quarter Report) and does not affect other periodic reports, which are up to date. Management explains that the delay stems from substantial time and resources being devoted to the company’s previously announced upcoming public offering and the related disclosures. Because of this focus, Akari states it could not complete the Form 10-Q (Quarter Report) on time without unreasonable effort or expense. The company indicates it expects to file the delayed Form 10-Q (Quarter Report) within the standard five-day extension allowed under SEC Rule 12b-25. Investors should therefore anticipate the quarterly filing to appear shortly after the original due date, assuming no further complications. Akari also warns that it expects a significant change in its results of operations for the quarter compared with the same period last year. The company anticipates recording a material non-cash impairment charge under U.S. GAAP, driven primarily by a sustained drop in its share price and market capitalization below the carrying value of its net assets. This impairment will affect the condensed consolidated statements of operations and comprehensive loss, but it does not directly impact cash flow. As with all forward-looking statements, the final figures may differ once the Form 10-Q (Quarter Report) is filed, and investors should watch for updated details in the full report. Akari notes that it has remained current on all other required SEC filings and is working to complete this quarter’s report within the permitted extension window. The notification was signed on May 18, 2026, by Kameel Farag, an authorized officer, underscoring the company’s intent to maintain regulatory compliance and transparency with shareholders. The most recent analyst rating on (AKTX) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page. Spark’s Take on AKTX Stock According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral. The score is primarily weighed down by weak financial performance (no revenue, ongoing losses, and continued cash burn) and bearish technicals (price far below key moving averages with negative MACD). These are partially offset by a strengthened balance sheet with very low debt and a financing-related corporate event that supports capital access, though potential dilution remains a consideration. To see Spark’s full report on AKTX stock, click here. More about Akari Therapeutics Average Trading Volume: 34,443 Technical Sentiment Signal: Sell Current Market Cap: $3.95M Learn more about AKTX stock on TipRanks’ Stock Analysis page.